Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock A Clinical Trial
Top Cited Papers
Open Access
- 1 November 2020
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 202 (9), 1253-1261
- https://doi.org/10.1164/rccm.201911-2172OC
Abstract
Rationale: Exogenous angiotensin II increases mean arterial pressure in patients with catecholamine-resistant vasodilatory shock (CRVS). We hypothesized that renin concentrations may identify patients most likely to benefit from such therapy. Objectives: To test the kinetic changes in renin concentrations and their prognostic value in patients with CRVS. Methods: We analyzed serum samples from patients enrolled in the ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) trial for renin, angiotensin I, and angiotensin II concentrations before the start of administration of angiotensin II or placebo and after 3 hours. Measurements and Main Results: Baseline serum renin concentration (normal range, 2.13-58.78 pg/ml) was above the upper limits of normal in 194 of 255 (76%) study patients with a median renin concentration of 172.7 pg/ml (interquartile range [IQR], 60.7 to 440.6 pg/ml), approximately threefold higher than the upper limit of normal. Renin concentrations correlated positively with angiotensin I/II ratios (r = 0.39; P<0.001). At 3 hours after initiation of angiotensin II therapy, there was a 54.3% reduction (IQR, 37.9% to 66.5% reduction) in renin concentration compared with a 14.1% reduction (IQR, 37.6% reduction to 5.1% increase) with placebo (P<0.0001). In patients with renin concentrations above the study population median, angiotensin II significantly reduced 28-day mortality to 28 of 55 (50.9%) patients compared with 51 of 73 patients (69.9%) treated with placebo (unstratified hazard ratio, 0.56; 95% confidence interval, 0.35 to 0.88; P = 0.012) (P = 0.048 for the interaction). Conclusions: The serum renin concentration is markedly elevated in CRVS and may identify patients for whom treatment with angiotensin II has a beneficial effect on clinical outcomes.Keywords
This publication has 30 references indexed in Scilit:
- Endothelial injury in sepsisIntensive Care Medicine, 2013
- Genetic Susceptibility to Non-Necrotizing Erysipelas/CellulitisPLOS ONE, 2013
- Recent advances involving the renin–angiotensin systemExperimental Cell Research, 2012
- Angiotensin II in experimental hyperdynamic sepsisCritical Care, 2009
- Physiology of Local Renin-Angiotensin SystemsPhysiological Reviews, 2006
- Hyperreninemic hypoaldosteronism: a possible etiological factor of septic shock-induced acute renal failureIntensive Care Medicine, 2003
- Additive Effects of Losartan and Enalapril on Blood Pressure and Plasma Active ReninHypertension, 1997
- Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertensionJournal Of Hypertension, 1996
- Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.Hypertension, 1993
- Effects of angiotensin I-converting enzyme inhibitor, SQ 14225, in nomal men.Endocrinologia Japonica, 1979